Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 plus LGX818 in adult patients with BRAF-mutant melanoma
NL-OMON40426Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib and encorafenib in melanoma and cutaneous malignancy (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Recommended phase II dose and 3 more. Started Feb 2014; status: active, not recruiting.
02
Drugs
ribociclibencorafenib
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON40426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40426.